U.S. Specialized REITs Stock News

Remitly Global stock jumped 7.7% today to US$25.93. That move came as investors reacted to a quarter that put profitability, not just growth, in the spotlight. Q2 revenue reached US$495 million while net income excluding special items came in at US$205.9 million, which is a sharp shift for a digital remittance platform that has spent years focused on scale. The main story is margin strength. Trailing net profit margin now sits at 16.9%, a significant increase from last year. The key question...

Why Horace Mann Educators Stock Is Back on Investors’ Radar Horace Mann Educators (HMN) has drawn fresh attention after reporting second quarter 2026 revenue of US$443.5 million and net income of US$41.6 million, with higher figures also reported for the first half of the year. See our latest analysis for Horace Mann Educators. The earnings update appears to have coincided with stronger interest in Horace Mann Educators, with the share price at US$54.12 and a 90 day share price return of...

In recent days, Autodesk has attracted heightened investor attention ahead of its 27 August 2026 earnings release, with analysts expecting year-over-year growth in both earnings per share and revenue. This focus on stronger anticipated earnings and sales underscores how closely investors are watching analyst forecasts as a gauge of Autodesk's operating momentum. With analysts projecting meaningful earnings and revenue growth, we'll now examine how this optimism could influence Autodesk's...

Novanta stock just jumped 6.7% in a single session, and that move highlights how emotionally charged this earnings season has become. The market responded to a clear headline of double digit revenue growth in Q2 and an increase to full year guidance. Beneath the excitement, the key drivers were margins and cash. Adjusted gross margin reached 47% and adjusted earnings per share rose at a double digit rate, while free cash flow for the quarter was about US$65 million. For a high multiple...

Huntsman (HUN) has drawn investor attention after reporting second quarter 2026 results along with a fresh dividend declaration. The update combines higher reported sales with a much smaller net loss and a continued cash payout. See our latest analysis for Huntsman. Despite the narrower loss and the continued dividend, Huntsman’s recent share price momentum has been weak, with a 7 day share price return down 16% and a 90 day share price return down 32%. Over a longer horizon, total...

Why Butterfly Network Stock Is Back on Investors’ Radar Butterfly Network (BFLY) is drawing fresh attention after raising its 2026 revenue outlook to US$119 million to US$123 million and issuing higher guidance for the third quarter following its latest earnings report. See our latest analysis for Butterfly Network. Butterfly Network’s raised guidance and stronger recent earnings sit alongside sharp share price momentum, with the stock posting a 30 day share price return of 9.5% and a 1 year...

With fresh US tariffs on imported polysilicon and new incentives for domestic production, the quiet world of semiconductor materials has suddenly moved to center stage. This policy shift could reshape where critical inputs for chips and solar panels are sourced, which matters for investors watching supply chains and pricing power. This article walks through 3 US semiconductor materials stocks exposed to this news and how each might fit, or might not fit, in a portfolio. The stocks highlighted...

Alpha Teknova stock rose 16.4% to close at US$6.53, capping a strong week for investors who were already sitting on solid short term gains. The market is focusing on one key development above all else. The headline result is that Q2 delivered the highest quarterly revenue in the company’s history, with more than US$12 million in sales and a clear step down in the quarterly net loss. That combination of record revenue and a narrower loss appears to have driven today’s shift in sentiment. The...

AbCellera Biologics jumped 10.3% to US$6.53 today, a sharp move for a stock that came into the print with a mixed recent run, up over the past week but down over the past month. The market is reacting to one thing above all else: the company is leaning hard into a high cash burn and deeper quarterly loss to fund its antibody pipeline, backed by a reported US$567 million cash pile and more than US$675 million of available liquidity. The question now is whether that liquidity cushion really...

Novo Nordisk (NYSE:NVO) has drawn fresh attention after recent share price moves, with the stock closing at US$45.97. Investors are weighing this level against its longer term returns and current fundamentals. See our latest analysis for Novo Nordisk. That jump in Novo Nordisk’s share price over the last session sits against a weaker backdrop, with the 7 day share price return down 10.93% and the year to date share price return down 12.25%. The 1 year total shareholder return is down 2.61%...

Evolus stock just ripped almost 20% higher to US$7.41, and the move is all about one thing. The market is latching onto a margin and profitability turn that feels very different from the company investors watched over the past year. Q2 revenue of US$84.1m, helped by aesthetics demand across toxins and fillers, arrived alongside a third straight quarter of positive adjusted earnings before interest, taxes, depreciation and amortization. That shift in earnings quality is what traders are...

Samsara Inc. recently announced that it will report its second-quarter fiscal 2027 results on September 3, 2026, after the U.S. market close, accompanied by a live webcast and subsequent replay on its investor relations site. This earnings date has sharpened the debate over whether Samsara’s strong recurring revenue growth and AI-enabled operations can justify its current premium valuation. We’ll now examine how this upcoming earnings release, set against questions about premium valuation,...

In early August 2026, Toast, Inc. reported Q2 results showing higher revenue and net income than a year earlier, completed a US$648.33 million share repurchase program, and saw its ongoing AI partnership with Google deepen while BWH Hotels endorsed Toast as a POS option across the U.S. and Canada. Together, the stronger profitability, expanding AI-driven integrations, and entry into large hospitality networks highlight Toast’s effort to deepen its ecosystem and broaden its customer reach...

Q2 2026 earnings snapshot Timken (TKR) has reported second quarter 2026 results, providing fresh data on how the business is performing across its bearings and industrial motion operations. For the quarter ended June 30, 2026, sales were US$1,260.9 million compared with US$1,173.4 million a year earlier. Net income was US$28.9 million compared with US$78.5 million in the prior year period. Basic earnings per share from continuing operations were US$0.42 compared with US$1.13 a year ago...

Recent Performance Context For SLM Stock SLM (SLM) has drawn investor interest after a period of mixed returns, with the stock higher over the past week, month and past 3 months, yet lower over the past year. At a recent close of US$27.41 and a market value of about US$5.2b, SLM sits against a backdrop of declining annual revenue and net income growth, which keeps the loan-focused business model in sharper focus for investors. See our latest analysis for SLM. SLM’s share price has gained over...

Conagra Brands (CAG) is back on investor radars after Conagra Brands Canada introduced Marigold, a chef-inspired Indian frozen entrée and cooking sauce line. This signals a fresh product push in the Canadian market. See our latest analysis for Conagra Brands. Despite the Marigold launch and recent leadership changes, Conagra Brands’ share price has had mixed momentum, with a 30 day share price return of 5.84% but a year to date share price decline of 14.16%. Over the longer term, the total...

Axsome Therapeutics stock has delivered a very large 5 year gain, yet the current set of valuation checks and market multiples together suggest the share price no longer looks obviously cheap or clearly overpriced. Axsome Therapeutics has returned roughly 7.6x over 5 years, which puts the recent pullback in the context of a very long running upswing that investors need to judge carefully. Expectations around Axsome Therapeutics turning its pipeline and portfolio into durable cash flow can...

In the second quarter of 2026, Precigen, Inc. reported revenue of US$54.98 million, net income of US$20.07 million, and diluted earnings per share from continuing operations of US$0.05, a sharp turnaround from the prior year’s loss-making period. This profitability was driven largely by rapid uptake of Papsimios, supported by expanded payer coverage to about 315 million US lives and seven-year FDA market exclusivity for adult recurrent respiratory papillomatosis. Next, we will examine how...

Why Universal Health Services Stock Is Back on Investors’ Radar Universal Health Services (UHS) has drawn fresh attention after reporting second quarter 2026 results and confirming completion of a long running share repurchase program that has been in place since July 2014. Both events give investors new information on recent operating performance and capital allocation choices as of late July 2026. Together they frame how you might think about the stock today. See our latest analysis for...

Park National Corporation recently reported second-quarter 2026 results, with net interest income rising to US$138.86 million and net income reaching US$58.75 million, alongside higher earnings per share versus a year earlier, and also declared a quarterly dividend of US$1.10 per share payable in September. While earnings and net interest income improved year over year for both the quarter and first half of 2026, the bank also recorded higher net loan charge-offs, highlighting both stronger...

Why Amprius Technologies Stock Is Back In Focus After Guidance And Earnings Amprius Technologies (AMPX) is in the spotlight after reporting record second quarter results and lifting its 2026 revenue outlook to at least US$140 million, alongside a narrower expected full year net loss. See our latest analysis for Amprius Technologies. The earnings beat and raised 2026 outlook have put Amprius Technologies back on traders’ radars. The share price at US$11.19 has seen mixed momentum, with a 7 day...

IQVIA Holdings (IQV) stock is back in focus after the company agreed a collaboration with Medera to support cardiac gene therapies and human based drug discovery platforms through its global clinical and regulatory infrastructure. See our latest analysis for IQVIA Holdings. The Medera collaboration sits alongside a series of recent updates from IQVIA Holdings, including raised 2026 revenue guidance, a detailed second quarter earnings release and ongoing share repurchases. It also comes after...

Oil and gas stocks are back in the spotlight as the Strait of Hormuz again sits at the center of geopolitics and Brent and WTI prices move sharply. For investors, this kind of stress test can quickly reshuffle which companies look resilient and which look exposed. This article breaks down how that news filters through to 3 energy sector stocks and what their different profiles might mean for your watchlist. The 3 stocks below are just a starting sample, and the full screen surfaced 40 more...

Gilead Sciences (GILD) is back in focus after reporting its strongest base business growth in three years, raising full year guidance for HIV sales and core operations despite sizable acquisition related net losses. See our latest analysis for Gilead Sciences. The current Gilead Sciences share price of US$130.86 sits against a year to date share price return of 7.62%, while total shareholder return over five years is 121.58%. That mix of modest recent share price movement and strong long term...